BGNE.US 6160.HK
BeiGene has a total of three marketed proprietary products.

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab.

Looking up: Novartis will provide transition services to BeiGene to ensure that key aspects of their co-development and commercialization of tislelizumab can proceed without disruption, including manufacturing, regulatory, safety and clinical support

Take Note: In July this year, Novartis withdrew from a TIGIT inhibitor project being developed by BeiGene, meaning the tislelizumab withdrawal is the second time the Swiss company has terminated a collaboration with BeiGene in just three months.

Digging Deeper: BeiGene currently has three proprietary products for sale. Two of those, Brukinsa, approved for the treatment of lymphoma in the U.S., and Tevimbra, a leader in the domestic PD-1 field, recorded strong sales growth this year. That helped to fuel a 74% jump in BeiGene’s second-quarter revenue to $595 million, and narrow its net loss by 27.1% to $730 million. But U.S. pharmaceutical giant AbbVie (ABBV.US) has accused BeiGene of patent infringement related to Brukinsa. That, combined with the end of two major agreements with Novartis, could throw a major wrench into BeiGene’s plans to expand overseas.

Market Reaction: BeiGene’s Hong Kong shares fell on Wednesday, closing down 4.8% at HK$120.90 by the midday break. The stock now trades in the middle of its 52-week range.

Translation by A. Au

Have a great investment idea but don’t know how to spread the word? We can help! Contact us for more details.

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Yatsen downgrades Q2 revenue outlook

Yatsen gets black eye from shopping fest blues

The operator of Perfect Diary cosmetics stores lowered its second-quarter revenue guidance by 10%, putting the figure back in contraction territory Key Takeaways: Yatsen lowered its revenue guidance by 10%…